Back to discover

Protein / target

Serine/threonine-protein kinase D3

Encoded byPRKD3O94806Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Diacylglycerol-dependent serine/threonine kinase

Strongest disease association

Hypertension

Via encoding gene PRKD3 · Genetic evidence · score 0.45

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC.

View complete UniProt function annotation

Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress (By similarity)

Subcellular location

CytoplasmMembrane
Domains and Gene Ontology detail (15)

Domains & features

PHProtein kinase

Gene Ontology

  • Ccytosol
  • Cplasma membrane
  • FATP binding
  • Fdiacylglycerol-dependent serine/threonine kinase activity
  • Fdiacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • Fkinase activity
  • Fprotein serine kinase activity
  • Fprotein serine/threonine kinase activity
  • Fzinc ion binding
  • Pintracellular signal transduction
  • Pphospholipase C-activating G protein-coupled receptor signaling pathway
  • Pprotein phosphorylation

890 aa · 100 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Kinase signallingGO
View supporting evidence

Kinase signalling

  • ·diacylglycerol-dependent serine/threonine kinase activity
  • ·diacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • ·kinase activity
  • ·protein serine kinase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

midostaurin
ApprovedInhibitor

Protein kinase C (PKC) inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PRKCI, PRKCA, PRKCG +7 more · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRKD3

Gene-level evidence surfaced through the gene PRKD3 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Leukemia, Myeloid, Acute
0.67Moderately supported

Clinical evidence dominant · Open Targets 0.54

Neoplasms
0.53Moderately supported

Clinical evidence dominant · Open Targets 0.40

Hypertension
0.46Limited support

Genetic evidence dominant · Open Targets 0.28

Schizophrenia
0.44Limited support

Genetic evidence dominant · Open Targets 0.27

Neurodegenerative Diseases
0.29Preliminary

Pathway evidence dominant · Open Targets 0.44 · no direct causal or clinical evidence

View evidence synthesis (5)
Leukemia, Myeloid, AcuteModerately supported
0.67
agreement 0.520.82
Clinical99%Literature1%

Open Targets aggregate 0.54 · 2 independent evidence families

NeoplasmsModerately supported
0.53
agreement 0.380.69
Clinical80%Literature20%

Open Targets aggregate 0.40 · 2 independent evidence families

HypertensionLimited support
0.46
agreement 0.340.57
Genetic100%

Open Targets aggregate 0.28 · 1 independent evidence family

SchizophreniaLimited support
0.44
agreement 0.320.56
Genetic100%

Open Targets aggregate 0.27 · 1 independent evidence family

Neurodegenerative DiseasesPreliminary
0.29
agreement 0.120.47
Pathway98%Literature2%

Open Targets aggregate 0.44 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Leukemia, Myeloid, Acute0.54
Neurodegenerative Diseases0.44
Neoplasms0.40
Hypertension0.28
Schizophrenia0.27

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (5)
GSK-690693Phase 1
SOTRASTAURINPhase 2
CEP-2563Phase 1
MIDOSTAURINApproval
UCN-01Phase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and High-Quality Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and human protein atlas loc) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Approved DrugSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · Human Protein Atlas locPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  2. New publication2017-07-24
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

    Leukemia · 2018 · 109 citations · Europe PMC · via midostaurin

  3. New publication2016-06-01
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

    The New England journal of medicine · 2016 · 371 citations · Europe PMC · via midostaurin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.